NovaBridge Biosciences
NASDAQ:NBPBiotechnology
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.90M
NBP Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
NovaBridge BiosciencesNASDAQ: NBP
Accumulated OCI · Q4 FY2025 · quarter ended Dec 2025
Accumulated OCI falls 97.6% from a year ago
Accumulated OCI stood at $5.94M at the end of Q4 FY2025, down 97.6% from a year earlier and down 99.7% from the prior quarter. Over 3 fiscal years it compounded at -69.9% a year.
Context
- Accumulated OCI amounted to 15.9% of total assets at the end of Q4 FY2025, up 0.3 pp from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -97.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 5.94M USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.94M | — |
| FY2024 | 2024-12-31 | 243.66M | +512.7% |
| FY2023 | 2023-12-31 | 39.77M | -81.6% |
| FY2022 | 2022-12-31 | 216.72M | +840.7% |
| FY2021 | 2021-12-31 | (29.26M) | — |
Accumulated OCI vs competitors
How NBP compares with its peers on the latest reported figures
- NBP's Dec 2025 Accumulated OCI of $5.94M is the highest of the 11 companies compared; the peer median is -$96.5K.
- Its year-over-year change of -97.6% is the 5th highest of 9, against a peer median of -88.7%.
- Accumulated OCI amounts to 15.9% of total assets for NBP, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
NBPNovaBridge Biosciences | Dec 2025 | $5.94M | -97.6% | -69.9% | 15.9% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $208K | +1464788732394466.3% | — | 0.1% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$26K | -620.0% | — | 0.0% | |
| Mar 2026 | -$81K | +11.0% | — | 0.0% | |
| Mar 2026 | -$112K | -314.8% | — | 0.0% | |
| Mar 2026 | -$207K | -297.1% | — | 0.2% | |
| Mar 2026 | -$268K | -159.6% | — | 0.1% | |
ENGNenGene Holdings Inc. | Apr 2026 | -$1.14M | -17.8% | — | 0.4% |
| Mar 2026 | -$5.22M | -4.4% | — | 1.6% | |
| Peer median (excluding NBP) | -$96.5K | -88.7% | — | 0.1% | |
Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 552.8M | 3.21B | 291.51M | 498.24M | 30.11M |
| Short-term Investments | 118.16M | 235.43M | 20.22M | 767.36M | 30.02K |
| Net Receivables | 60.95M | 4.81M | 1.83M | 8.55M | 256.33K |
| Inventory | 4.27M | (80.28M) | 0 | 0 | 0 |
| Other Current Assets | 0 | 242.96M | 15.68M | 1 | 0 |
| Total Current Assets | 750.18M | 3.63B | 329.91M | 1.29B | 31.1M |
| Property, Plant & Equipment (Net) | 24.87M | 123.97M | 5.55M | 27.72M | 421.59K |
| Goodwill | 25.51M | 162.57M | 0 | 0 | 0 |
| Intangible Assets | 18.77M | 118.89M | 0 | 0 | 0 |
| Long-term Investments | 55.24M | 30.85M | 0 | 224.98M | 5.32M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.18M | 10.91M | 33.46M | 9.96M | 402K |
| Total Non-current Assets | 128.56M | 447.19M | 39.01M | 262.66M | 6.15M |
| Total Assets | 878.74M | 4.07B | 368.92M | 1.55B | 37.24M |
| Account Payables | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 0 | 2.75M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 371.66K | 2.19M | 0 | 773.67K | 0 |
| Other Current Liabilities | 0 | 549.85M | 49.67M | 5.01M | 1.31M |
| Total Current Liabilities | 97.9M | 659.74M | 58.14M | 61.7M | 3.84M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 37.49M | 0 | 106K | 0 | 0 |
| Other Non-current Liabilities | 15.2M | 373.53M | 64.83M | 3.8K | 73.05K |
| Total Non-current Liabilities | 65.52M | 405.6M | 68.19M | 22.38M | 384.13K |
| Total Liabilities | 163.42M | 1.07B | 126.34M | 84.08M | 4.23M |
| Common Stock | 19.77K | 132K | 19K | 138.68K | 3.86K |
| Retained Earnings | (683.21M) | (6.77B) | (1.26B) | (9.39B) | (190.47M) |
| Accumulated OCI | (29.26M) | 216.72M | 39.77M | 243.66M | 5.94M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 715.33M | 3.01B | 242.58M | 1.47B | 33.02M |
| Total Debt | 17.64M | 38.29M | 3.89M | 28.33M | 438.46K |
| Net Debt | (535.16M) | (3.18B) | (287.62M) | (469.9M) | (29.67M) |
NovaBridge Biosciences
NASDAQ:NBP
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.